David Sunseri, Ph.D., President & Chief Executive Officer
David Sunseri, Ph.D. is President and Chief Executive Officer at Haematologic Technologies (HTI). David is responsible for leading the next phase of HTI’s growth, solidifying and expanding HTI’s position as a leading Contract Research Organization focused on large molecules and an innovator of biologic reagents and sample collection devices for research and diagnostic markets.
David served as CEO of PMI BioPharma Solutions, a specialty CDMO providing protein-based research, target validation, functional characterization, advanced assay development, and GMP manufacturing services. He led the company through a transition from pharmaceutical ownership to a private company focused on CRO and CDMO services until its sale to private equity in 2020.
Prior to PMI, David spent almost four years at Berg, LLC, in positions of increasing responsibility leading all aspects of CMC during this time. Most recently, he was the Vice President, Product Development responsible for clinical trial manufacturing, engineering operations, supply chain, and formulations. Dave spent approximately 10 years with Schering-Plough and Merck in small molecule inhalation and parenteral development and commercial manufacturing of inhalation and medical device products.
David received his bachelor’s degree in chemistry from the University of North Alabama and Ph.D. In Analytical Chemistry, specializing in Chromatography, from Florida State University under the direction of John G. Dorsey.
He serves on the University of North Alabama Foundation Board of Directors and is a member of the University of North Alabama’s College of Arts and Sciences advisory council.
Ryan Dorfman, Ph.D., Vice President, Operations
Dr. Dorfman has over 25 years of experience in the field of Protein Biochemistry with expertise in Thrombosis and Hemostasis. He is an accomplished scientist, project leader, and manager in the biotech industry.
Dr. Dorfman received his B.S. degree in Biochemistry from Marietta College and his Ph.D. Degree in Biochemistry from Temple University. Since completion of his Ph.D. degree in 2000, Dr. Dorfman began working for Haematologic Technologies, Inc. and has served as Senior Scientist, Scientific Director, and Vice President of Operations. Currently, he provides scientific leadership and business acumen for both HTI and Haemtech Biopharma Services.
John Maddalena, Ph.D., Vice President, Operations of Haemtech Biopharma Services
Dr. Maddalena joined Haematologic Technologies in 1992, and was responsible for the development and implementation of a Quality Management System (QMS), and subsequent ISO 9001 registration, to support HTI’s manufacturing activities. More recently, Dr. Maddalena assumed oversight responsibilities for Haemtech Biopharma Services, a division of HTI that focuses on providing analytical testing services to support the development and release of protein therapeutics. He specializes in the development and validation of analytical test methods.
Dr. Maddalena received his B.S. in Microbiology from the University of Notre Dame, and his Ph.D. in Cellular and Molecular Biology from the University of Vermont. Dr. Maddalena also holds a M.Ed. degree from the University of Massachusetts.
Steve Pemberton, Vice President Commercial Development
Steve Pemberton has over 25 years of experience developing commercial sales and marketing teams for life sciences and in-vitro diagnostics companies. Mr. Pemberton is responsible for all external commercial activities for Haematologic Technologies including expanding customer access to HTI’s cutting-edge capabilities in large molecule bio-analytics, plasma protein reagents, and custom collection devices.
Mr. Pemberton has held previous leadership positions at Bionique Testing Laboratories, a leader in Mycoplasma testing for the biotech and pharmaceutical industry, Rheonix, Inc., a developer and manufacturer of molecular diagnostics tests kits and instruments where Steve led Business Development, Sales, Marketing, and product development through two successful rounds of venture capital funding. Previous positions include sales and marketing leadership roles at Roche Diagnostics and Abbott Laboratories. Steve graduated from Arizona State University and is a licensed Medical Technologist, (MT, ASCP).
Vivian Bills, Finance Director/Chief Administration Officer
Ms. Bills joined Haematologic Technologies in 1995 and oversees the company’s functions of accounting, policies and procedures, financial analysis, and reporting. She is responsible for all administrative services including office services, human resources, and benefits management.
Ms. Bills received a Bachelor of Arts degree in English Literature from the University of Vermont.